Multicenter Evaluation of Morbidity and Predictors of Response to Imiquimod Treatment for Penile Intraepithelial Neoplasia
2024

Study on Imiquimod Treatment for Penile Intraepithelial Neoplasia

Sample size: 44 publication Evidence: moderate

Author Information

Author(s): Avitan Ofir, Elst Laura, Vreeburg Manon, Rafael Tynisha, Jordanova Katja, Graafland Niels, Hendricksen Kees, van Rhijn Bas W.G., van der Poel Henk G., Albersen Maarten, Brouwer Oscar

Primary Institution: Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital

Hypothesis

What are the morbidity and predictors of response to imiquimod treatment for penile intraepithelial neoplasia?

Conclusion

The study found a 64% complete response rate to imiquimod treatment, but many patients experienced side effects and local recurrence.

Supporting Evidence

  • 64% of patients achieved a complete response to imiquimod treatment.
  • 25% of patients with a complete response experienced local recurrence within 3 years.
  • 50% of the overall cohort reported side effects, mainly local pain and irritation.

Takeaway

Doctors tested a cream called imiquimod to treat a skin problem on the penis, and while it worked for many, half of the patients had some side effects.

Methodology

A retrospective multicenter study involving patients diagnosed with penile intraepithelial neoplasia treated with imiquimod from 2010 to 2022.

Potential Biases

Potential selection bias due to the retrospective nature and small cohort size.

Limitations

The study had a small sample size and incomplete documentation of HPV status and side effects.

Participant Demographics

Median age of participants was 65.4 years, with a range of 56 to 72 years.

Statistical Information

P-Value

0.4

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1016/j.euros.2024.08.020

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication